CoChat

Glucagon‐like peptide‐1 (GLP‐1): a trial of treatment in non‐insulin‐dependent diabetes mellitus

Open access
TODD, J. F., WILDING, J. P. H., EDWARDS, C. M. B., KHAN, F. A., GHATEI, M. A., BLOOM, S. R. · 1997 · European Journal of Clinical Investigation
Cited by 87

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Abstract

Glucagon‐like peptide‐1 (7–36) amide (GLP‐1) is released from the gut into the circulation after meals and is the most potent physiological insulinotropic hormone in man. In contrast to presently available therapeutic agents for non‐insulin‐dependent diabetes mellitus (NIDDM), GLP‐1 has the advantages of both suppressing glucagon secretion and delaying gastric emptying. We report the first chronic study of subcutaneous (s/c) GLP‐1 treatment in NIDDM. Five patients with poorly controlled NIDDM were entered into a six‐week, double‐blind crossover trial. Each received three weeks treatment with s/c GLP‐1 40 nmol or saline, given three times a day immediately before meals. A standardized test meal was given at the beginning and end of each treatment period. GLP‐1 reduced plasma glucose area under the curve (AUC) following the standard test meal by 25% (AUC, 0–180 mins, GLP‐1 start of treatment 482.2 ± 38.2 vs. saline start of treatment 635.7 ± 45.4 mmol min L−1, F = 16.4, P < 0.02). The beneficial effect of GLP‐1 on plasma glucose concentration was fully maintained for the three‐week treatment period. Plasma glucagon levels were significantly lower for 60 min postprandially after GLP‐1 treatment. In this group of patients there was no significant increase in postprandial insulin levels with GLP–1. We have demonstrated a significant improvement in postprandial glycaemic control with s/c GLP‐1 treatment that was fully maintained over a three‐week treatment period. GLP‐1 improves glycaemic control even in the absence of an insulinotropic effect and is a potential treatment for NIDDM.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1046/j.1365-2362.1997.1490691.x

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 87

Metadata

Authors
TODD, J. F., WILDING, J. P. H., EDWARDS, C. M. B., KHAN, F. A., GHATEI, M. A., & BLOOM, S. R.
Venue
European Journal of Clinical Investigation
Publisher
Wiley
Published
1997-06
Volume
27
Issue
6
Pages
533-536
ISSN
  • 0014-2972 (ISSN-L)
  • 1365-2362
OpenAlex
W2103960782
Cited by
87
References
1
FWCI
3.10
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Glucagon‐like peptide‐1 (GLP‐1): a trial of treatment in non‐insulin‐dependent diabetes mellitus. https://app.cochat.ai/papers/10.1046/j.1365-2362.1997.1490691.x
The paper
TODD, J. F., WILDING, J. P. H., EDWARDS, C. M. B., KHAN, F. A., GHATEI, M. A., & BLOOM, S. R. (1997). Glucagon‐like peptide‐1 (GLP‐1): a trial of treatment in non‐insulin‐dependent diabetes mellitus. European Journal of Clinical Investigation. https://doi.org/10.1046/j.1365-2362.1997.1490691.x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.